Tag: Drug Development

Drug development is the process of bringing a new pharmaceutical drug to the market once a lead compound has been identified through the process of drug discovery. It includes pre-clinical research on microorganisms and animals, filing for regulatory status for an investigational new drug to initiate clinical trials on humans, and may include the step of obtaining regulatory approval with a new drug application to market the drug.

Innate Biologics and The Wistar Institute started a research collaboration

Innate Biologics is working with Wistar to develop a first-of-its-kind recombinant protein platform, which specifically targets intracellular inflammatory signaling pathways.

AstraZeneca’s hyperkalaemia drug is approved in the EU

AstraZeneca announced that the European Commission has granted marketing authorisation for Lokelma for the treatment of adults with hyperkalaemia.

Scientists from Kazan developed a drug for muscle weakness

Biologists from Kazan have developed a new drug capable of suppressing myasthenia (muscle weakness) without inducing strong side effects. The scientists tested new drug in rats and human bladder tissue samples.

BIOCAD opens new laboratory to develop biologics

BIOCAD, a biotech company, has opened a new lab in one of its R&D centers located in the village of Lyubuchany, Moscow region, where it plans to use unique technology to develop biological drugs.

CBT Pharmaceuticals licenses a novel recombinant antibody from Crown Bioscience

laboratory test
The agreement gives CBT exclusive world-wide development and commercialization rights to a novel, recombinant, human monoclonal antibody which targets a differentiated epitope on the cytotoxic T-lymphocyte antigen-4 molecule.

Dracen Pharmaceuticals will advance its novel immuno-metabolism pipeline

drug development
Dracen will use this financing, obtained from Deerfield, an investment management firm, to progress its programs into clinical trials for patients suffering from cancer.

Medicxi launches a new drug development initiative

Medicxi, the leading European life sciences investment firm, announced a new initiative named ‘The Foundation Institute for 21st Century Medicine’ based in Cambridge, U.K.

French biotech DEINOVE entered a license agreement with Redx Pharma

microbiology plates
DEINOVE, a French biotech company that discovers, develops, and produces high-value compounds from rare bacteria, signed a license option agreement with the British drug discovery company Redx Pharma.

Prothena starts collaboration with Celgene to develop new neuroscience therapies

drug development
Prothena Corporation, a biotechnology company focused on the discovery, development of therapies in the neuroscience, announced a collaboration with Celgene to develop new therapies for a range of neurodegenerative diseases.

Novo Nordisk obesity drug showed promising results during clinical trial

novo nordisk
Semaglutide, developed by Novo Nordisk, is an analogue of the human glucagon-like peptide (GLP-1) hormone, and induces weight loss by reducing hunger, increasing feelings of fullness and helping people eat less.

Bavarian Nordic set up a partnership with US Department of Defense

Bavarian Nordic announced the signing of a new alliance with the US Department of Defense for the development of a prophylactic vaccine against the equine encephalitis virus—a rare, but potentially deadly mosquito-borne illness.

ChemRar has started the production of HIV drug

ChemRar, a Russian company based in the business incubator of the city of Khimki, began to produce a drug for HIV‐infected patients. This is not a cure for AIDS, but a so-called “preventive drug”.

Lundbeck acquires Prexton Therapeutics

By acquiring Prexton, Lundbeck will obtain global rights of an attractive compound which currently is in clinical phase II testing for symptomatic treatment of OFF-time reduction in Parkinson's disease and dyskinesia.

United BioPharma begin to build a new biopharmaceutical manufacturing plant

United BioPharma (UBP), a Chinese clinical stage biotech company, announced the beginning of construction of a state-of-the-art biopharmaceutical manufacturing plant in China.

argenx obtained a €2.5 million grant to develop antibody-based therapies

argenx, a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies, received a €2.5 million grant from Flanders Innovation and Entrepreneurship (VLAIO).

Covance creates a global immunology and immunotoxicology unit

LabCorp, a leading global life sciences company, announced that its Covance Drug Development business has formed a global immunology and immunotoxicology (I&I) unit dedicated to the specific needs of biologic drug development.